Statins in the prevention of transplant coronary artery disease: In pediatric heart recipients

Pediatric Transplantation

Volumn 11, Issue 5, 2007, Pages 459-460

  Pahl, Elfriede ^a,b  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ANTIINFLAMMATORY ACTIVITY; CORONARY ARTERY DISEASE; DRUG CHOICE; DRUG SAFETY; DRUG USE; EDITORIAL; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; PEDIATRIC SURGERY; VASCULAR DISEASE;

ADULT; CHILD; CHOLESTEROL, HDL; CORONARY DISEASE; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 34447340588     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00710.x     Document Type: Editorial

References (13)

1. Hedman M, Pahlman R, Sundvall J, et al. Low HDL cholesterol predicts the onset of transplant vasculopathy in pediatric cardiac recipients on pravastatin therapy. Pediatr Transplant 2007, DOI: 10.1111/j.1399-3046.2007.00690.x
2. Singh TP, Naftel DC, Webber S, et al. Hyperlipidemia in children after heart transplantation. J Heart Lung Transplant 2006 : 25 : 1199 1205.
3. Chin C, Rosenthal D, Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant 2000 : 4 : 193 199.
4. Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: Initial experience with pravastatin. J Heart Lung Transplant 2004 : 23 : 317 322.
5. Chin C, Gamberg P, Miller J, Luikart H, Bernstein D. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant 2002 : 21 : 1213 1217.
6. Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001 : 20 : 611 618.
7. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 2005 : 24 : 63 66.
8. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995 : 333 : 621 627.
9. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005 : 24 : 1736 1740.
10. Seipelt IM, Seipelt R, Pahl E, et al. Neointimal inflammation and adventitial angiogenesis correlate with severity of cardiac allograft vasculopathy in pediatric recipients. J Heart Lung Transplant 2005 : 24 : 1039 45.
11. Pahl E, Naftel DC, Kuhn MA, et al. The impact and outcome of transplant coronary artery disease in a pediatric population: A 9-year multi-institutional study. J Heart Lung Transplant 2005 : 24 : 645 651.
12. Armstrong AK, Goldberg CS, Crowley DC, et al. Effect of age on lipid profiles in pediatric heart transplant recipients. Pediatr Transplant 2005 : 9 : 523 530.
13. Law YM, Yim R, Agatisa P, et al. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens. J Heart Lung Transplant 2006 : 25 : 276 282.